Cinaciguat, a soluble guanylate cyclase activator for the potential treatment of acute heart failure

Current Opinion in Investigational Drugs

Volumn 11, Issue 9, 2010, Pages 1039-1047

  Tamargo, Juan ^a   Duarte, Juan ^a   Caballero, Ricardo ^a   Delpón, Eva ^a  

^a SCHOOL OF MEDICINE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 [[4 CARBOXYBUTYL[2 [(4 PHENETHYLBENZYL)OXY]PHENETHYL]AMINO]METHYL]BENZOIC ACID; ALDOSTERONE; BETA ACTIN; COLLAGEN; CREATININE; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE INHIBITOR; GLYCERYL TRINITRATE; GUANYLATE CYCLASE; IRON; ISOPRENALINE; KT 5283; LINSIDOMINE; LIPOPOLYSACCHARIDE; NATRIURETIC PEPTIDE RECEPTOR B; NITRIC OXIDE; PHENYLEPHRINE; RENIN; SODIUM; THROMBOPLASTIN; THROMBOXANE A2; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UREA;

ACUTE HEART FAILURE; ANTICOAGULATION; ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; BLOOD PRESSURE; CENTRAL VENOUS PRESSURE; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; CREATININE BLOOD LEVEL; DIURESIS; DOG; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; HEADACHE; HEART; HEART INFARCTION SIZE; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE CELL; HEART MUSCLE RELAXATION; HEART OUTPUT; HEART RATE; HEART RIGHT ATRIUM PRESSURE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART STROKE VOLUME; HEMODYNAMICS; HOT FLUSH; HUMAN; HYPOTENSION; IC 50; KIDNEY BLOOD FLOW; LAMB; LIVER CIRRHOSIS; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; LUNG VASOCONSTRICTION; NAUSEA; NONHUMAN; OXIDATIVE STRESS; PENIS ERECTION; PLASMA RENIN ACTIVITY; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; RABBIT; REVIEW; SIDE EFFECT; SODIUM EXCRETION; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE RICH PLASMA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VASODILATATION;

ACUTE DISEASE; ANIMALS; BENZOIC ACIDS; CARDIOVASCULAR SYSTEM; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATORS; GUANYLATE CYCLASE; HEART FAILURE; HEMODYNAMICS; HUMANS; MALE; VASODILATOR AGENTS;

EID: 77956234709     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. NO-and haem-independent activation of soluble guanylyl cyclase: Molecular basis and cardiovascular implications of a new pharmacological principle. Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M, Heil M, Minuth T, Perzborn E, Pleiss U, Schramm M et al. BR J RMACOL, 2002, 136, 5, 773-783.
2. Cardiorenal and humoral actions of the new heme-independent direct soluble guanylate cyclase activator BAY 58-2667 in experimental congestive heart failure. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Harty GJ, Lapp H, Stasch JP, Burnett JC CIRCULATION 2003 108 17 Suppl IV-398
3. NO-independent activation of soluble guanylate cyclise prevents disease progression in rats with 5/6 nephrectomy. Kalk P, Godes M, Relle K, Rothkegel C, Hucke A, Stasch JP, Hocher B BRIT J PHARMACOL 2006 148 6 853-859
4. Bayer: Investor handout Q3 | 2006. Bayer AG COMPANY PRESENTATION 2006 November 29
5. Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Lapp H, Stasch JP, Burnett JC HYPERTENSION 2007 49 5 1128-1133
6. Inhibition of TGF-â induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. Dunkern TR, Feurstein D, Rossi GA, Sabatini F, Hatzelmann A EUR J PHARMACOL 2007 572 1 12-22
7. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, Kumar A, Meurer S, Deile M, Taye A, Knorr A, Lapp H, Muller H et al J CLIN INVEST, 2006, 116, 9, 2552-2561.
8. Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase. Schmidt PM, Schramm M, Schroder H, Wunder F, Stasch JP J BIOL CHEM 2004 279 4 3025-3032
9. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Dumitrascu R, Weissmann N, Ghofrani HA, Dony E, Beuerlein K, Schmidt H, Stasch JP, Gnoth MJ, Seeger W, Grimminger F, Schermuly RT CIRCULATION 2006 113 2 286-295
10. A cell-based cGMP assay useful for ultra-high-throughput screening and identification of modulators of the nitric oxide/cGMP pathway. Wunder F, Stasch JP, Hütter J, Alonso-Alija C, Hüser J, Lohrmann E ANAL BIOCHEM 2005 339 1 104-112
11. Identification of residues crucially involved in soluble guanylate cyclase activation. Rothkegal C, Schmidt PM, Stoll F, Schroder H, Schmidt HH, Stasch JP FEBS LETT 2006 580 17 4205-4213
12. Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase. Schmidt P, Schramm M, Schroder H, Stasch JP EUR J PHARMACOL 2003 468 3 167-174
13. NO-independent activation of soluble guanylate cylase prevents disease progression in rats with 5/6 nephrectomy. Kalk P, Godes M, Relle K, Rothkegel C, Hucke A, Stasch JP, Hocher B NEPHROL DIAL TRANSPLANT, 2006 21 Suppl 4, 38-39.
14. Coordination of the prosthetic HEME moiety at the soluble guanylate ciclase. Schmidt PM, Rothkegel C, Wunder F, Schroeder H, Stasch JP NAUNYN SCHMIEDEBERGS ARCH PHARMACOL, 2005, 371, Suppl 1, R40.
15. Potent cardiorenal actions in experimental heart failure with dual activation of soluble and particulate guanylate cyclases by BAY 58-2667 and brain-type natriuretic peptide: A novel therapeutic strategy. Boerrigter G, Costello-Boerrigter LC, Lapp H, Harty GJ, Stasch JP, Burnett JC EUR HEART J, 2004, 25, Suppl S Abs, P1098
16. Receptor binding assay for nitric oxide- and heme-independent activators of soluble guanylate ciclase. Schmidt P, Schramm M, Schroeder H, Stasch JP ANAL BIOCHEM 2003 314 1 162-165
17. NO-independent stimulators and activators of soluble guanylate cyclase: Discovery and therapeutic potential. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP NAT REV DRUG DISCOV 2006 5 9 755-768
18. BAY 58-2667, a novel NO-independent activator of soluble guanylate cyclase attenuates myocardial infarction following ischemia/reperfusion injury through protein kinase G activation. Ockaili RA, Salloum FN, Chau VQ, Lall SK, Kukreja RC AM HEART ASSOC SCIENTIFIC SESSIONS 2008 November 12 Abs 5861
19. 27th Annual J.P. Morgan healthcare conference. Bayer AG JP MORGAN ANN HEALTHCARE CONF 2009 January 12
20. Discovery of riociguat (BAY 63-2521): A potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. Mittendorf J, Weigand S, Alonso-Alija C, Bischoff E, Feurer A, Gerisch M, Kern A, Knorr A, Lang D, Muenter K, Radtke M et al CHEMMEDCHEM 2009 4 5 853-865
21. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A et al EUR HEART J 2008 29 19 2388-2442
22. BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts. Krieg T, Liu Y, Rütz T, Methner C, Yang XM, Dost T, Felix SB, Stasch JP, Cohen MV, Downey JM EUR HEART J 2009 30 13 1607-1613
23. Sanofi-aventis delivers double-digit EPS(1) growth in 2009 as the transformation program progresses. Sanofi-aventis PRESS RELEASE 2010 February 10
24. 28th Annual J.P. Morgan healthcare conference. Bayer AG JP MORGAN ANN HEALTHCARE CONF 2010 January 12
25. Population pharmacokinetics and pharmacodynamics of cinaciguat, a soluble guanylate cyclase activator, in patients with acute decompensated heart failure. Mueck W, Frey R CLIN PHARMACOKINET 2010 49 2 119-129
26. Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers. Frey R, Muck W, Unger S, Artmeier-Brandt U, Weimann G, Wensing G J CLIN PHARMACOL 2008 48 12 1400-1410
27. Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Lapp H, Mitrovic V, Franz N, Heuer H, Buerke M, Wolfertz J, Mueck W, Unger S, Wensing G, Frey R CIRCULATION 2009 119 12 2781-2788
28. Role of guanylate cyclase modulators in decompensated heart failure. Mitrovic V, Hernandez AF, Meyer M, Gheorghiade M HEART FAIL REV 2009 14 309-319
29. Soluble guanylate cyclase agonists inhibit expression and procoagulant activity of tissue factor. Sovershaev MA, Egorina EM, Hansen JB, Osterud B, Pacher P, Stasch JP, Evgenov OV ARTERIOSCLER THROMB VASC BIOL 2009 29 10 1578-1586
30. Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury. Korkmaz S, Radovits T, Barnucz E, Hirschberg K, Neugebauer P, Loganathan S CIRCULATION 2009 120 8 677-686
31. Cinaciguat, a soluble guanylate cyclise activator, causes potent and sustained pulmonary vasodilatation in the ovine fetus. Chester M, Tourneux P, Seedorf G, Grover TR, Gien J, Abam SH AM J PHYSIOL LUNG CELL MOL PHYSIOL 2009 297 2 L318-L325
32. Guanylate cyclase and the NO/cGMP signaling pathway. Denninger JW, Marletta MA BIOCHIM BIOPHYS ACTA 1999 1411 2-3 334-350
33. Guanylyl cyclases and signaling by cyclic GMP. Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik KP, Waldman SA PHARMACOL REV 2000 52 3 375-413
34. Soluble guanylate cyclase: An old therapeutic target re-visited. Hobbs AJ BRIT J PHARMACOL 2002 136 5 637-640
35. Modulation of cGMP in heart failure: A new therapeutic paradigm. Boerrigter G, Lapp H, Burnett JC HANDB EXP PHARMACOL, 2009, 191, 485-506.
36. Soluble guanylyl cyclase: Structure and regulation. Koesling D, Friebe A REV PHYSIOL BIOCHEM PHARMACOL 1999 135 41-65
37. Homodimerization of soluble guanylyl cyclase subunits. Dimerization analysis using a glutathione S-transferase affinity tag. Zabel U, Hausler C, Weeger M, Schmidt HHHW J BIOL CHEM 1999 274 18149-18152
38. Cyclic nucleotide research-still expanding after half century. Beavo JA, Brunton LL NAT REV MOL CELL BIOL 2002 3 9 710-718
39. Vasodilator dysfunction in aged spontaneously hypertensive rats: Changes in NO synthase III and soluble guanylyl cyclase expression, and in superoxide anion production. Bauersachs J, Bouloumié A, Mülsch A, Wiemer G, Fleming I, Busse R CARDIOVASC RES, 1998, 37, 3, 772-779.
40. Endothelial function: Cardiac events. Lerman A, Zeiher AM CIRCULATION 2005 111 3 363-368
41. Do we still need organic nitrates? Münzel T, Wenzel P, Daiber A J AM COLL CARDIOL 2007 49 12 1296-1298
42. Intravenous nitroglycerin in the treatment of decompensated heart failure: Potential benefits and limitations. Elkayam U, Bitar F, Akhter MW, Khan S, Patrus S, Derakhshani M J CARDIOVASC PHARMACOL THER 2004 9 4 227-241
43. Adverse effects of nitroglycerin treatment on endothelial function, vascular nitrotyrosine levels and cGMP-dependent protein kinase activity in hyperlipidemic Watanabe rabbits. Warnholtz A, Mollnau H, Heitzer T, Kontush A, Moller-Bertram T, Lavall D, Giaid A, Beisiegel U, Marklund SL, Walter U, Meinertz T, Munzel T J AM COLL CARDIOL 2002 40 7 1356-1363
44. Executive summary: HFSA 2006 comprehensive heart failure practice guideline. Adams KF, Lindenfeld J, Arnold JMO
45. Investigational positive inotropic agents for acute heart failure. Tamargo J, Caballero R, Gómez R, Barana A, Amoros I, Delpón E CARDIOVASC HAEMATOL DISORDERS-DRUG TARGET 2009 9 3 193-205
46. New investigational drugs for the management of acute heart failure syndromes. Tamargo J, Amorós I, Barana A, Caballero R, Delpón E CURRENT MED CHEM 2010 17 4 363-390
47. NO/redox disequilibrium in the failing heart and cardiovascular system. Hare JM, Stamler JS J CLIN INVEST 2005 115 3 509-517
48. NO- and haem-independent soluble guanylate cyclase activators. Schmidt HH, Schmidt PM, Stasch JP HANDB EXP PHARMACOL, 2009, 191, 309-339.
49. Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation. Meurer S, Pioch S, Pabst T, Opitz N, Schmidt PM, Beckhaus T, Wagner K, Matt S, Gegenbauer K, Geschka S, Karas M et al CIRC RES, 2009, 105, 1, 33-41.
50. Beyond NO and heme: Biochemical and pharmacological opportunities. Rothkegel C, Schmidt PM, Kumar A, Stoll F, Lapp H, Wunder F, Schröder H, Rinke M, Schmidt HHHW, Stasch JP BMC PHARMACOL 2005 5 S1
51. Inhaled agonist of soluble guanylate cyclase induce selective pulmonary vasodilation. Evgenov OV, Kohane DS, Bloch KD, Stasch JP, Volpato GP, Bellas E, Evgenov NV, Buys ES, Gnoth MJ, Graveline AR, Liu R et al AM J RESPIR CRIT CARE MED, 2007, 176, 11,1138-1145.
52. Cinaciguat, a soluble guanylate cyclase activator, unloads the heart in acute decompensated heart failure. Erdmann E, Semigran MJ, Nieminen MS, Agrawal R, Mitrovic V, Mebazaa A J AM COLL CARDIOL 2010 55 Abs A16
53. Pharmacokinetics of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in patients with hepatic impairment. Frey R, Mueck W, Unger S, Schmidt A, Wensing G EUR J HEART FAIL 2010 9 Suppl Abs S14.
54. Renal impairment does not alter the pharmacokinetics of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667). Lettieri JT, Mazzu A, Frey R, Mueck W, Silang R, Smith W, Marbury T, Cannon C, Lasseter K, Sundaresan PR EUR J HEART FAIL 2010 9 Suppl Abs S184
55. Nitrate resistance and tolerance: Potential limitations in the treatment of congestive heart failure. Elkayam U, Mehra A, Shotan A, Ostrzega E AM J CARDIOL 1992 70 8 98B-104B
56. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Cotter G, Metzkor E, Kaluski E, Faigenberg Z, Miller R, Simovitz A, Shaham O, Marghitay D, Koren M, Blatt A, Golik A et al LANCET, 1998, 351, 9100, 389-393.
57. Pulmonary edema: New insight on pathogenesis and treatment. Cotter G, Kaluski E, Moshkovitz Y, Milovanov O, Krakover R, Vered Z CURR OPIN CARDIOL 2001 16 3 159-163.
58. Nitrate therapy is an alternative to furosemide/morphine therapy in the management of acute cardiogenic pulmonary edema. Beltrame JF, Zeitz CJ, Unger SA, Brennan RJ, Hunt A, Moran JL, Horowitz JD J CARD FAIL 1998 4 4 271-279
59. New investigational drugs for the management of acute heart failure syndromes. Tamargo J, Amoros I, Barana A, Caballero R, Delpon E CURR MED CHEM 2010 17 4 363-390
60. Effect of enalapril initiated early after acute myocardial infarction on heart failure parameters, with reference to clinical class and echocardiographic determinants. CONSENSUS II Multi-Echo Study Group. Edner M, Bonarjee VV, Nilsen DW, Berning J, Carstensen S, Caidahl K CLIN CARDIOL 1996 19 7 543-548
61. Absolute quantitation of coronary steal induced by intravenous dipyridamole. Akinboboye OO, Idris O, Chou RL, Sciacca RR, Cannon PJ, Bergmann SR J AM COLL CARDIOL 2001 37 1 109-116